Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
leukemia
Novel drug preventing protein recycling shows potential for treating leukemia
By Dross at 2007-04-22 00:47
 

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemiaterm in animal models by preventing cancer cells from being purged of damaged proteins.

 

In the March online issue of the journal Blood, investigators reported that the new proteasome inhibitor, NPI-0052, not only successfully kills leukemia cells, but also shows greater efficacy than its predecessor bortezomib when combined with other agents in animal models.

According to researchers, proteasomes clean out mutated or damaged proteins within cells, which promotes cell growth and allows cancer cells to rapidly reproduce. Proteasome inhibitors block this process, resulting in apoptosis, or cell death, of the malignant cells.

read more | 1 comment | 1276 reads

Knocking Out Survival Protein Could Aid Leukemia Treatment
By Dross at 2007-04-22 00:44
 

An effective way to fight leukemiaterm might be to knock out a specific protein that protects cancer cells from dying, a new study shows.

The findings suggest that a drug that can block this “survival protein” might on its own be an effective therapy.

But such a drug used in combination with several existing drugs might also offer an effective one-two punch against drug-resistant forms of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). The two forms of cancer kill about 20,500 Americans yearly.

read more | 2003 reads

Major Gene Study Uncovers Secrets of Leukemia
By Dross at 2007-03-08 09:11
 

 

The St. Jude team used microarrays, postage-stamp-sized chips that contain DNA fragments, which allowed researchers to investigate more than 350,000 markers called single nucleotide polymorphisms. Single nucleotide polymorphisms are individual variations in the DNA that are spaced across the human chromosomes. Single nucleotide polymorphisms function as flags for researchers, allowing them to detect specific deletions of DNA in a gene or increases in the number of specific genes at a level of detail that was previously unattainable. The St. Jude group used this approach to analyze leukemiaterm samples from 242 pediatric patients with ALL. This identified an unexpectedly high frequency of mutations involving genes that function as master regulators of normal B-cell development and differentiation.

read more | 1766 reads

Leukemia - Unraveling the complex regulation of stem cells: implications for aging and cancer
By Dross at 2007-02-09 22:05
 

AS in other articles submitted today, research is finding both internal and external factors effect the health of blood stem cells in the bone marrow. Many centers were testing the use of forteo, an osteoparosis medication, in order to increase the density of the matrix the cells live in. Now further research, reviewed in this article at Nature, is beginning to match interior and exterior cell events. The authors summarize how these regulatory mechanisms facilitate various aspects of normal stem cell biology and extend the discussion to their involvement in aging and tumorigeneisis, two biological phenomena intimately tied to stem cells. They speculate that aberrant epigenetic events and altered miRNA expression profiles in aged stem cell populations play important roles in carcinogenesis.

read more | 1550 reads

Role for proteomics in identifying hematologic malignancies
By Dross at 2007-01-12 01:32
 

 

BOSTON - Scientists have identified a set of biomarkers that could help clinicians identify a group of hematologic malignancies known as myelodysplastic syndromes (MDS), which affect approximately 300,000 individuals worldwide and often progress to acute myeloid leukemiaterm. Reported in the advance issue of the Proceedings of the National Academy of Sciences (which appears on-line the week of January 8) the findings point to a possible new diagnostic method for these malignancies, which occur when blood cells remain in an immature stage within the bone marrow and never sufficiently develop into the mature cells necessary for proper hematologic functioning.

read more | 2 comments | 1539 reads

Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mo
By admin at 2006-12-14 02:17
 

[via ScienceDirect - Cancer Cell : Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia]:A challenge for the development of therapies selectively targeting leukemic stem cells in acute myeloid leukemia (AML) is their similarity to normal hematopoietic stem cells (HSCs). Here we demonstrate that the leukemia-propagating cell in murine CALM/AF10-positive AML differs from normal HSCs by B220 surface expression and immunoglobulin heavy chain rearrangement. Furthermore, depletion of B220 cells in leukemic transplants impaired development of leukemia in recipients. As in the murine model, human CALM/AF10-positive AML was characterized by CD45RA (B220)-positive, IG DH-JH rearranged leukemic cells. These data demonstrate in a murine leukemia model that AML can be propagated by a transformed progenitor with lymphoid characteristics, which can be targeted by antibodies that do not crossreact with normal HSCs.

read more | 1799 reads

Efficacy and safety of thalidomide in patients with acute myeloid leukemia
By admin at 2006-12-05 03:36
 

[via leukemia-research : Message: Re: [leukemia-research] Digest Number 62]:

Martin B. Steins, Teresa Padre, Ralf Bieker, Sandra Ruiz, Martin Kropff, Joachim Kienast, Torsten Kessler, Thomas Buechner, Wolfgang E. Berdel, and Rolf M. Mesters From the Department of Medicine/Hematology and Oncology, University of Muenster, Germany.

 

Emerging data suggest an involvement of angiogenesis in the pathophysiology of acute myeloid leukemiaterm (AML). Thus, antiangiogenic therapy could constitute a novel strategy for the treatment of AML. To test this hypothesis, a phase I/II dose-escalating trial was performed to study the safety and efficacy of thalidomide, a putative inhibitor of angiogenesis, in 20 patients with AML. Thirteen patients were assessable for both toxicity and response, tolerating a maximum dose of 200 to 400 mg daily for at least 1 month. Seven patients had to be prematurely withdrawn from drug administration owing to progressive disease and death (3 patients), personal decision (2 patients), or inability to tolerate thalidomide (2 patients).

read more | 2484 reads

Abbott Introduces CE-Marked DNA Tests in Europe for the Detection of Chromosomal Abnormalities Associated With Leukemia
By admin at 2006-12-05 02:36
 

 

DELKENHEIM, Germany, Abbott Molecular today announced that it has introduced six CE-marked DNA tests in Europe for use by diagnostic laboratories in identifying chromosomal abnormalities associated with certain forms of leukemiaterm, a cancer of the white blood cells originating in the bone marrow.

 

The tests are based on Abbott's proprietary fluorescence in situ hybridization technology (FISH) and employ DNA probes used to detect genetic abnormalities, such as extra or rearranged chromosomes, common in patients with acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). DNA probes are molecules stained with fluorescent dyes that recognize and bind to specific target molecules in patient samples. The fluorescent probes can be viewed under a special microscope, enabling the detection of chromosome gains, deletions or translocations. The FISH tests are intended to supplement conventional cytogenetics (the analysis of chromosomes) and in some cases provide additional information not detected by other test methods. Conventional cytogenetics, for example, may indicate if large chromosome changes have occurred, whereas the FISH method targets specific, more cryptic chromosome defects known to be associated with cancers. Both methods are needed to tell treating physicians whether a particular cancer is present or has recurred and to determine the patient's prognosis. "Combining traditional cytogenetics with FISH testing provides doctors with the accurate information they need to make better decisions regarding treatment options and quality of life," said Prof. Christine Harrison, director, Leukaemiaterm Research Fund Cytogenetics Group, Southampton General Hospital, UK "Certain genetic aberrations can be important indicators of whether a patient has a particularly aggressive form of leukemia or whether they will respond to certain therapies," said Timothy Stenzel, M.D., Ph.D., medical director, Abbott Molecular. "Abbott's FISH technology helps physicians diagnose different leukemias that may look similar but have different genetic abnormalities and therefore may require different treatment." The following six probes have received CE mark certification, allowing them to be commercially marketed in the European Union. They include the Vysis(R) LSI(R) p53/LSI ATM and LSI D13S319/LSI 13q34/CEP 12 Multi-Color Probe Sets; Vysis LSI BCR/ABL Dual Color, Dual Fusion Translocation Probe Set (20 assays and 50 assays); Vysis LSI BCR/ABL ES Dual Color Translocation Probe Set; Vysis LSI BCR/ABL Dual Color, Single Fusion Translocation Probe Set; Vysis LSI MLL Dual Color, Break Apart Rearrangement Probe; and Vysis LSI 21 SpectrumOrange(TM) Probe. The six probes are already available in the United States. These products represent the first in a series of CE-marked DNA probes that Abbott Molecular expects to launch in Europe in the coming months. Future probes will be offered for a variety of applications in cancer and genetic testing. About Abbott Molecular Abbott Molecular is a leader in the development and commercialization of FISH probes, offering a broad menu of tests for use in cancer diagnostics and genetic testing. The technology allows highly sensitive, direct detection of chromosomal abnormalities. It also permits the quantitative assessment of morphological changes in cells, enabling clinicians to investigate DNA in its native, chromosomal form within the cell nucleus. As correlations between genetic anomalies and disease are established, Abbott Molecular applies its technologies to develop clinical diagnostic products intended to provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases.

read more | 997 reads

Familial (inherited) leukemia, lymphoma, and myeloma: an overview.
By admin at 2006-11-22 11:03
 

* Segel GB, * Lichtman MA. Department of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA.

 

We have reviewed the world's literature that addresses familial leukemiaterm, lymphomaterm, and myeloma. We have catalogued the phenotypic abnormalities associated with an increased risk of developing a hematological malignancy. These syndromes, such as Fanconi anemia or familial platelet syndrome, have been well characterized and in many cases the gene responsible for the predisposition has been defined. We have focused, however, on reports of a familial incidence of hematological malignancy in which no prior predisposing syndrome was reported. In this circumstance, so-called pure familial leukemia, lymphoma, or myeloma, the intergenerational incidence of disease occurred in ostensibly healthy persons. These families have been grouped into sets in which (a) anticipation, (b) immune abnormalities, (c) linkage to HLA phenotypes, (d) linkage to chromosome abnormalities, or (e) gene abnormalities have been reported.

read more | 3078 reads

Targeting Leukemic Stem Cells by BCL-2 Inhibition
By admin at 2006-11-18 04:40
 

HOUSTON, Nov. 17 /PRNewswire/ -- Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemiaterm (AML) blastterm, progenitor and even stem cells that are often resistant to standard chemotherapyterm treatment.

The drug was powerful in its own right, the researchers say, but they found that some AML cells were themselves resistant to ABT-737, so they added another drug that knocked out this secondary resistance. Together, these agents may provide a powerful therapy against AML, and could form the basis of a new way to treat the cancer, say the scientists, whose study was published in the November 14 issue of the journal, Cancer Cell.

read more | 2270 reads

Australian Discovery Could Lead To New Leukemia Treatments
By admin at 2006-11-14 22:43
 

The protein-- Stat5 -- was investigated at a laboratory at Deakin University's Melbourne Campus at Burwood, as part of a multicentre international collaboration. leukemiaterm is a cancer caused by a proliferation of white blood cells.

 

To understand and help prevent the disease, the Deakin researchers are looking for the responsible genes. Head of the Deakin team, Associate Professor Alister Ward, said the discovery of how the protein acts provides a breakthrough in understanding the onset of leukemia. "We have found that Stat5 is responsible for making white blood cells overgrow in a particular disease setting that often precedes leukemia," Associate Professor Ward explained. "On top of this, we have also found that Stat5, when activated, is sufficient on its own to cause white blood cells to overgrow inside a whole organism. "Together, these findings identify Stat5 as a major player in the process of leukemia progression and is therefore a worthwhile target for intervention." Associate Professor Ward said the next step in this research was to utilise the model systems established to develop new therapeutics.

2008 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 05:15 PM.